Drug profile · INN
moricizine hydrochloride
ETHMOZINE
moricizine hydrochloride (ETHMOZINE) is a sodium channel alpha subunit blocker. Route of administration: oral. Current US regulatory status: approved.
Drug details — moricizine hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
moricizine hydrochloride (ETHMOZINE) is a sodium channel alpha subunit blocker. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium channel alpha subunit blocker
Primary target: Sodium channel alpha subunit
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is moricizine hydrochloride?
moricizine hydrochloride (ETHMOZINE) is a sodium channel alpha subunit blocker. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for moricizine hydrochloride?
ETHMOZINE is a marketed brand name for moricizine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of moricizine hydrochloride?
moricizine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.